CanSino Biologics (688185.SH): Application for the registration of the adsorbed acellular pertussis (five-component) combined vaccine has been accepted.

According to the Zhitong Financial APP, CanSino (688185.SH) announced that the company's research and development of the adsorbed acellular pentavalent DTP combined vaccine (for ages 6 and above) (referred to as "Td5cp for adolescents and adults") has recently received the "Acceptance Notification" issued by the National Medical Products Administration for its domestic drug registration application (referred to as "drug registration application"). Td5cp for adolescents and adults is suitable for individuals aged 6 and above and serves as a booster vaccine for tetanus, diphtheria, and pertussis. This vaccine has been included in routine vaccination programs in many developed countries, but there are currently no approved booster vaccines for adolescents and adults in China. If this product successfully enters the market, it will fill a gap in the domestic market.